[{"id":"0d0b2e4e-1f61-4cfe-b739-4d640eaf2deb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01730118","created_at":"2021-01-18T07:33:26.542Z","updated_at":"2024-07-02T16:36:04.159Z","phase":"Phase 1","brief_title":"Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing","source_id_and_acronym":"NCT01730118","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK","pipe":" | ","alterations":" HR positive • HER-2 expression","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AdHER2/neu DC Vaccine"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 03/04/2013","start_date":" 03/04/2013","primary_txt":" Primary completion: 12/03/2019","primary_completion_date":" 12/03/2019","study_txt":" Completion: 12/03/2019","study_completion_date":" 12/03/2019","last_update_posted":"2022-09-10"}]